Celltrion Inc (068270.KS)
Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets biopharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P44 that is in phase 3 clinical trial for the treatment of multiple myeloma; CT-P51, which is in phase 3 clinical trial for the treatment of Melanoma, lung cancer; CT-P53, which is in phase 3 clinical trial for the treatment of multiple sclerosis; and CT-P55 that is in phase 3 clinical trial for the treatment of Psoriasis. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.
Company Info
Highlights
₩35.14T
₩3.66T
₩1.82T
₩150,400.00 - ₩200,165.36
₩225,952.38
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Celltrion Inc (068270.KS) returned -14.13% year-to-date (YTD) and -3.68% over the past 12 months. Over the past 10 years, 068270.KS delivered an annualized return of 12.13%, outperforming the S&P 500 benchmark at 10.85%.
068270.KS
-14.13%
-0.86%
-9.24%
-3.68%
3.39%
-2.81%
12.13%
^GSPC (Benchmark)
0.51%
3.96%
-2.00%
12.02%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of 068270.KS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -4.16% | 2.39% | -8.15% | -4.56% | -0.19% | -14.13% | |||||||
| 2024 | -10.82% | 0.00% | 6.40% | -1.15% | -6.77% | -1.08% | 17.33% | -0.73% | -3.74% | -6.60% | 2.47% | 5.69% | -1.91% |
| 2023 | 1.99% | -11.30% | 3.17% | 7.21% | 6.66% | -10.74% | -4.12% | -1.84% | -3.27% | 7.40% | 8.96% | 24.02% | 25.88% |
| 2022 | -23.74% | 2.98% | 10.29% | 2.62% | -8.81% | 11.21% | 6.44% | -0.26% | -7.39% | 9.40% | -8.33% | -4.95% | -15.51% |
| 2021 | -9.75% | -8.18% | 9.08% | -18.03% | 3.20% | -2.19% | -5.59% | 15.58% | -11.43% | -22.74% | 3.24% | -2.09% | -43.54% |
| 2020 | -8.84% | 3.03% | 34.71% | -8.08% | 1.43% | 43.33% | -3.10% | 0.17% | -13.30% | -6.41% | 41.08% | 7.70% | 102.31% |
| 2019 | -1.57% | -6.62% | -11.49% | 17.13% | -10.38% | 8.16% | -17.03% | -7.92% | 4.46% | 21.95% | -13.00% | 9.22% | -14.58% |
| 2018 | 42.79% | 11.82% | -12.32% | -12.44% | -2.03% | 14.31% | -10.54% | -0.55% | 10.00% | -26.77% | 10.11% | -5.24% | 2.65% |
| 2017 | -6.70% | 1.30% | -11.23% | -0.55% | 6.70% | 20.40% | -5.73% | 6.08% | 23.37% | 21.90% | 15.60% | 12.70% | 109.98% |
| 2016 | 32.66% | -10.79% | 9.80% | -8.38% | -1.49% | -3.03% | 8.32% | 2.59% | -0.37% | -0.19% | -3.58% | 10.13% | 33.46% |
| 2015 | 4.76% | 60.93% | 6.72% | 22.60% | -19.49% | 13.04% | -0.13% | -8.86% | -4.37% | 13.40% | 12.08% | 0.85% | 124.03% |
| 2014 | 16.69% | 7.15% | -8.24% | 9.32% | 1.14% | -4.32% | -14.39% | 4.52% | 17.53% | -14.30% | -5.01% | 2.37% | 6.37% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 068270.KS is 31, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Celltrion Inc (068270.KS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Celltrion Inc provided a 0.44% dividend yield over the last twelve months, with an annual payout of ₩714.29 per share. The company has been increasing its dividends for 2 consecutive years.
| Period | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Dividend | ₩714.29 | ₩714.29 | ₩476.19 | ₩357.14 | ₩686.81 |
Dividend yield | 0.44% | 0.38% | 0.25% | 0.23% | 0.38% |
Monthly Dividends
The table displays the monthly dividend distributions for Celltrion Inc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | |||||||
| 2024 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩714.29 | ₩714.29 |
| 2023 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩476.19 | ₩476.19 |
| 2022 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩0.00 | ₩357.14 | ₩357.14 |
| 2021 | ₩686.81 | ₩686.81 |
Dividend Yield & Payout
Dividend Yield
Celltrion Inc has a dividend yield of 0.44%, which signifies it pays a smaller percentage of its stock price in dividends to its shareholders compared to other companies in the market.
Payout Ratio
Celltrion Inc has a payout ratio of 28.95%, which is quite average when compared to the overall market. This suggests that Celltrion Inc strikes a balance between reinvesting profits for growth and paying dividends to shareholders.
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Celltrion Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Celltrion Inc was 93.58%, occurring on Jan 23, 2008. Recovery took 756 trading sessions.
The current Celltrion Inc drawdown is 54.11%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -93.58% | Mar 5, 2007 | 220 | Jan 23, 2008 | 756 | Jan 17, 2011 | 976 |
| -64.45% | Dec 8, 2020 | 695 | Oct 5, 2023 | — | — | — |
| -61.36% | Mar 6, 2018 | 363 | Aug 26, 2019 | 315 | Dec 3, 2020 | 678 |
| -60.11% | Feb 24, 2006 | 161 | Oct 19, 2006 | 92 | Mar 2, 2007 | 253 |
| -54.3% | Jun 1, 2012 | 222 | Apr 22, 2013 | 69 | Jul 31, 2013 | 291 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Celltrion Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Celltrion Inc, comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -33.0%.
Valuation
The Valuation section provides an overview of how Celltrion Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 068270.KS relative to other companies in the Biotechnology industry. Currently, 068270.KS has a P/S ratio of 9.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 068270.KS in comparison with other companies in the Biotechnology industry. Currently, 068270.KS has a P/B value of 2.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |